Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Holders of 5% or more of ICCC
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Immucell Corp, largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Knudsen Ejnar A III | 13D/A | 9.21%832.8K shares | – | Nov 20, 20251 filing | Nov 20, 2025 | SEC |
| SRK Fund I, LP | 13D/A | 6.40%502.3K shares | +1.40 ppfrom 5.00% | May 22, 20242 filings | Sep 17, 2024 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Immucell Corp, newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Nov 20, 20254:36 PM ET | Knudsen Ejnar A III | 13D/A | 9.21%832.8K shares | – | Nov 19, 2025 | SEC |
| Sep 17, 20241:49 PM ET | SRK Fund I, LPand 2 others | 13D/A | 6.40%502.3K shares | +1.40 ppfrom 5.00% | Sep 17, 2024 | SEC |
| May 22, 20244:50 PM ET | SRK Fund I, LPand 2 others | 13D | 5.00%391.3K shares | New | May 22, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Immucell Corp shares.
No Form 144 notices for Immucell Corp are on file.